(Journal Article): Effect of Losartan on the mRNA Expressions of MT3-MMP and TIMP-2 in Diabetic Kidneys
 
Ding HL, Xu MT, Guo Y, Chen L, Zhang SL, Li F, Fu ZZ (Department of Endocrinology, The Second Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510120, China, helinding(at)tom.com )
 
IN: Rev Diabetic Stud 2005; 2(4):216-220
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: BACKGROUND and OBJECTIVES: The renin-angiotensin system plays a critical role in circulatory homoeostasis. Evidence has emerged that suggests a pathologic role for angiotensin II in patients with kidney disease. Losartan is an antagonist of angiotensin II and blocks the angiotensin II type-1 receptor. Thus it may reduce proteinuria and delay the progression of renal disease in diabetic nephropathy. We investigated the effects of losartan on the mRNA expressions of membrane-type3 matrix metalloproteinases (MT3-MMP) and the tissue inhibitor of metalloproteinase-2 (TIMP-2) in diabetic kidneys in order to evaluate degradation and remodeling of the extracellular matrix. METHODS: Male Wistar rats were divided into 3 groups. Group A was the control group containing healthy rats (n = 11), group B comprised diabetic rats without any therapy (n = 11), and group C consisted of diabetic rats treated with losartan (n = 9). 24-hr urine samples were collected in order to measure urinary albumin excretion (UAE). After a period of 18 weeks, the kidneys were extracted from all rats in order to measure the mRNA expressions of MT3-MMP, TIMP-2 and transforming growth factor-β1 (TGF-β1) by RT-PCR. We also examined the glomerular basement membrane thickening and the mesangial matrix (MM) density (MM area/mesangial area). RESULTS: The expression of renal MT3-MMP mRNA in group B (1.37 ± 0.96) was significantly higher than that in group A (0.75 ± 0.34, p < 0.05), but also significantly higher than in group C (0.75 ± 0.30, p < 0.05). Similarly, the mRNA expression of renal TIMP-2 in group B (0.73 ± 0.37) was significantly increased compared to that in group A (0.32 ± 0.19, p < 0.05), but also higher than in group C (0.34 ± 0.17, p < 0.05). In addition, subjects in group B showed abundant TGF-β1 mRNA expression and UAE compared to groups A and C, as well as significantly higher glomerular basement membrane thickening and MM density (all p < 0.05). CONCLUSIONS: We conclude that MT3-MMP and TIMP-2 production in the renal cortex of diabetic kidneys is increased. Losartan can prevent the development of diabetic nephropathy by decreasing MT3-MMP and TIMP2 production in diabetic kidneys.

TYPE OF PUBLICATION: Original article

REFERENCES:

1. McLennan SV, Fisher EJ, Yue DK, Turtle JR. High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy. Diabetes 1994. 43(8):1041-1045.
2. Davies M, Martin J, Thomas GJ, Lovett DH. Proteinases and glomerular matrix turnover. Kidney Int 1992. 41(3):671-678.
3. Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998. 54(3):775-784.
4. Bolbrinker J, Markovic S, Wehland M, Melenhorst WB, van Goor H, Kreutz R. Expression and response to Angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with Renin-dependent hypertension. J Pharmacol Exp Ther 2006. 316(1):8-16.
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001. 345(12):861-868.
6. Reckelhoff JF, Tygart VL, Racusen LC, Dzielak DJ. Glomerular metalloprotease activity in streptozotocin-treated rats and in spontaneously diabetic rats (BB/DP). Life Sci 1994. 55(12):941-950.
7. Lupia E, Elliot SJ, Lenz O, Zheng F, Hattori M, Striker GE, Striker LJ. IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. Diabetes 1999. 48(8):1638-1644.
8. Del Prete D, Anglani F, Forino M, Ceol M, Fioretto P, Nosadini R, Baggio B, Gambaro G. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 1997. 40(12):1449-1454.
9. Romanic AM, Burns-Kurtis CL, Ao Z, Arleth AJ, Ohlstein EH. Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients. Am J Physiol Renal Physiol 2001. 281(2):F309-317.
10. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, Seiki M, Okada Y. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997. 57(10):2055-2260.
11. Shankland SJ, Ly H, Thai K, Scholey JW. Glomerular expression of tissue inhibitor of metalloproteinase (TIMP-1) in normal and diabetic rats. J Am Soc Nephrol 1996. 7(1):97-104.
12. McLennan SV, Martell SY, Yue DK. High glucose concentration inhibits the expression of membrane type metalloproteinase by mesangial cells: possible role in mesangium accumulation. Diabetologia 2000. 43(5):642-648.
13. Caenazzo C, Garbisa S, Onisto M, Zampieri M, Baggio B, Gambaro G. Effect of glucose and heparin on mesangial alpha 1(IV)COLL and MMP-2/TIMP-2 mRNA expression. Nephrol Dial Transplant 1997. 12(3):443-448.
14. Baricos WH, Cortez SL, Deboisblanc M, Xin S. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 1999. 10(4):790-795.